natgillin/translations-raw huggingface dataset:
When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose). 
Ob uvedbi zdravljenja s posakonazolom je treba bolnikom, ki že prejemajo takrolimus, odmerek takrolimusa zmanjšati (npr. na približno tretjino trenutnega odmerka).
Investigations Uncommon: 
Preiskave Občasni:
Since certain adverse reactions (e.g. dizziness, somnolence, etc.) have been reported with posaconazole use, which potentially may affect driving/operating machinery, caution needs to be used. 
Ker so med uporabo posakonazola poročali o nekaterih neželenih učinkih (npr. omotici, zaspanosti, itd.), ki lahko poslabšajo sposobnost vožnje in upravljanja s stroji, je potrebna previdnost.
200 mg three times daily 
200 mg trikrat na dan
When administered through a peripheral venous catheter, the infusion should be administered over approximately 30 minutes. 
Če je zdravilo uporabljeno po perifernem venskem katetru, mora infundiranje trajati približno 30 minut.
Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine) 
Zaviralci kalcijevih kanalčkov, ki se presnovijo s CYP3A4 (npr. diltiazem, verapamil, nifedipin, nizoldipin)
HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and atorvastatin) 
Zaviralci reduktaze HMG-CoA, ki se presnovijo s CYP3A4 (npr. simvastatin, lovastatin in atorvastatin)
Noxafil gastro-resistant tablets are yellow-coated and capsule-shaped, debossed “100” on one side packaged in a blister in cartons of 24 (2x12) or 96 (8x12) tablets. 
Noxafil gastrorezistentne tablete so rumene, obložene tablete v obliki kapsule ter imajo na eni strani vtisnjeno oznako "100"; pakirane so v pretisnih omotih v škatlah, ki vsebujejo po 24 (2 x 12) ali 96 (8 x 12) tablet.
For patients with AML or MDS, prophylaxis with Noxafil should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm 
Pri bolnikih z AML ali MDS je treba profilakso z zdravilom Noxafil začeti več dni pred pričakovanim pojavom nevtropenije in naj traja še 7 dni po zvečanju števila nevtrofilcev nad 500 celic/mm
Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. 
Sočasna uporaba fosamprenavirja in posakonazola lahko zmanjša koncentracijo posakonazola v plazmi.
• tacrolimus and sirolimus (used during or after transplant surgery) 
• takrolimus in sirolimus (uporabljata se med ali po presaditvah),
When administered through a peripheral venous catheter, the infusion should be administered over approximately 30 minutes to reduce the likelihood of infusion site reactions (see section 4.8). 
Če je zdravilo dano po perifernem venskem katetru, mora infundiranje trajati približno 30 minut, da se zmanjša verjetnost reakcij na mestu infundiranja (glejte poglavje 4.8).
Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus. 
Dokazano je, da posakonazol in vitro deluje proti naslednjim mikroorganizmom: vrsti Aspergillus (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), vrsti Candida (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, in vrstam Fusarium, Rhizomucor, Mucor in Rhizopus.
• ciclosporin (used during or after transplant surgery) 
• ciklosporin (uporablja se med ali po presaditvah),
If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended. 
V primeru sočasne uporabe je priporočljivo skrbno spremljanje celotne krvne slike in neželenih učinkov, povezanih s povečano koncentracijo rifabutina (npr. uveitisa).
The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient. 
Učinek sočasne uporabe posakonazola na plazemske koncentracije substratov CYP3A4 se lahko razlikuje tudi pri posameznem bolniku.
Posaconazole tablets are absorbed with a median Tmax of 4 to 5 hours and exhibits dose proportional pharmacokinetics after single and multiple dosing up to 300 mg. 
Tablete posakonazola se absorbirajo s srednjo vrednostjo tmax od 4 do 5 ur in imajo po enkratnem in večkratnih odmerkih do 300 mg odmerku sorazmerno farmakokinetiko.
The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period. 
Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanih oziroma verjetnih invazivnih glivnih okužb, ki jih je ugotavljala neodvisna skupina zunanjih strokovnjakov na slep način med obdobjem zdravljenja.
• rifabutin (used to treat certain infections) 
• rifabutin (uporablja se za zdravljenje določenih okužb),
The primary efficacy endpoint was the incidence of proven/probable IFIs at 16 weeks post-randomisation as determined by an independent, blinded external expert panel. 
Primarni opazovani dogodek učinkovitosti je bila pojavnost dokazanih oziroma verjetnih invazivnih glivnih okužb 16 tednov po randomizaciji, ki jih je ugotavljala neodvisna skupina zunanjih strokovnjakov na slep način.
Noxafil contains glucose 
Zdravilo Noxafil vsebuje glukozo
The most frequently reported adverse reaction (>25 %) with an onset during the posaconazole intravenous phase of dosing with 300 mg once daily was diarrhoea (32 %). 
Najpogosteje poročani neželeni učinek (> 25 %), ki se je pojavil med intravensko fazo uporabe posakonazola v odmerku 300 mg enkrat na dan, je bila driska (32 %).
Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose. 
Pri zdravih prostovoljcih je bilo opravljenih več študij medsebojnega delovanja posakonazola z drugimi zdravili, pri katerih je bila izpostavljenost posakonazolu večja kot pri bolnikih, ki so prejemali enak odmerek.
If you develop severe diarrhoea or vomiting (being sick) while taking Noxafil, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly. 
Če se med jemanjem zdravila Noxafil pojavita huda driska ali bruhanje (slabost), se takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, kajti lahko preprečita pravilno delovanje zdravila.
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates) Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated. 
Terfenadin, astemizol, cisaprid, pimozid, halofantrin in kinidin (substrati CYP3A4) Sočasna uporaba posakonazola in terfenadina, astemizola, cisaprida, pimozida, halofantrina ali kinidina je kontraindicirana.
The most common adverse reaction (>1 %) leading to discontinuation of posaconazole concentrate for solution for infusion 300 mg once daily was AML (1 %). 
Najpogostejši neželeni učinek (> 1 %), ki je povzročil prekinitev uporabe posakonazola v koncentratu za raztopino za infundiranje v odmerku 300 mg enkrat na dan, je bila AML (1 %).
Excipient with known effect: This medicinal product contains approximately 1.75 g of glucose per 5 mL of suspension. 
Pomožna snov z znanim učinkom: To zdravilo vsebuje približno 1,75 g glukoze v 5 ml suspenzije.
Posaconazole does not have any major circulating metabolites and its concentrations are unlikely to be altered by inhibitors of CYP450 enzymes. 
Posakonazol v obtoku nima nobenega glavnega presnovka in ni verjetno, da bi zaviralci encimov CYP450 vplivali na njegovo koncentracijo.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below. 
Sočasna uporaba posakonazola in substratov CYP3A4 lahko zelo poveča izpostavljenost tem substratom, kot kažejo spodaj opisani učinki na takrolimus, sirolimus, atazanavir in midazolam.
The study treated 155 (65 %) subjects with AML or MDS, and 82 (35 %) subjects with HSCT, as the primary diseases at study entry. 
Primarni razlog zdravljenja v študiji sta bila ob vstopu v študijo AML ali MDS pri 155 (65 %) preiskovancih in HSCT pri 82 (35 %) preiskovancih.
The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole. 
Zdravljenje s posakonazolom je trajalo povprečno 80 dni in s flukonazolom 77 dni.
Following a single dose administration of 300 mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC0-72 hours and Cmax were higher compared to administration under fasted condition (51 % and 16 % for AUC0-72 hours and Cmax respectively). 
Po enkratnem odmerku 300 mg posakonazola v tabletah po zelo mastnem obroku sta bili pri zdravih prostovoljcih AUC0-72 ur in Cmax večji kot po uporabi na tešče (AUC0-72 ur 51 % in Cmax 16 %).
adrenal insufficiency, blood gonadotropin decreased pseudoaldosteronism 
insuficienca nadledvične žleze, znižana raven gonadotropinov v krvi psevdoaldosteronizem
Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients (see sections 4.2 and 5.2). 
Pri bolnikih z okvaro jeter je treba posakonazol uporabljati previdno, ker je kliničnih izkušenj malo in ker obstaja možnost, da je koncentracija posakonazola v plazmi pri teh bolnikih višja (glejte poglavji 4.2 in 5.2).
The AUC of posaconazole is: 4 times greater when administered with a highfat meal (~ 50 grams fat) and about 2.6 times greater when administered during a non-fat meal or nutritional supplement (14 grams fat) relative to the fasted state (see sections 4.2 and 4.5). 
Vrednost AUC za posakonazol je 4-krat večja, če ga bolnik zaužije skupaj z zelo mastnim obrokom (~ 50 gramov maščobe) in približno 2,6-krat večja pri zaužitju z nemastnim obrokom ali s prehranskim dodatkom (14 gramov maščobe) v primerjavi s stanjem na tešče (glejte poglavji 4.2 in 4.5).
During clinical trials, patients who received posaconazole oral suspension doses up to 1,600 mg/day experienced no different adverse reactions from those reported with patients at the lower doses. 
Med kliničnimi preskušanji niso bili neželeni učinki pri bolnikih, ki so dobili peroralno suspenzijo posakonazola v odmerkih do 1.600 mg/dan, nič drugačni od neželenih učinkov, o katerih so poročali pri bolnikih, ki so dobivali manjše odmerke.
No dose adjustment is recommended for patients with mild to severe hepatic impairment but caution is advised due to the potential for higher plasma exposure. 
Bolnikom z blago do hudo okvaro jeter odmerka sicer ni treba prilagoditi, a je zaradi možne večje plazemske izpostavljenosti priporočljiva previdnost.
However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended. 
Ker pa se posakonazol skozi ledvice ne izloča v pomembni meri, ni pričakovati, da bi huda okvara ledvic vplivala na farmakokinetiko posakonazola; prilagajanje odmerka tako ni potrebno.
Noxafil concentrate for solution for infusion will be diluted to the correct concentration by your pharmacist or nurse. 
Zdravilo Noxafil koncentrat za raztopino za infundiranje bosta farmacevt ali medicinska sestra razredčila na ustrezno koncentracijo.
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). 
Sočasni uporabi posakonazola in rifabutina se je treba izogibati, razen če korist za bolnika odtehta tveganje (glejte zgoraj za učinke rifabutina na plazemsko koncentracijo posakonazola).
Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4. 
Posakonazol lahko bistveno poveča plazemsko koncentracijo zaviralcev reduktaze HMG-CoA, ki se presnovijo s CYP3A4.
Following administration of 300 mg posaconazole concentrate for solution for infusion over 90 minutes, mean peak plasma concentration at the end of infusion was 3280 ng/mL (74 % CV). 
Po uporabi 300 mg posakonazola v koncentratu za raztopino za infundiranje v 90 minutah je bila povprečna največja koncentracija na koncu infundiranja 3.280 ng/ml (74 % KV).
If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse reactions, plasma concentrations of the CYP3A4 substrate and/or adverse reactions should be closely monitored and the dose adjusted as needed. 
Med sočasno uporabo posakonazola in peroralnih substratov CYP3A4, pri katerih lahko povečanje plazemske koncentracije spremljajo nesprejemljivi neželeni učinki, je treba skrbno spremljati plazemske koncentracije substrata CYP3A4 in/ali neželene učinke in po potrebi prilagoditi odmerek zdravila.
Due to the variability in exposure, patients with severe renal impairment should be monitored closely for breakthrough fungal infections (see section 4.2). 
Zaradi variabilne izpostavljenosti je treba bolnike s hudo okvaro ledvic skrbno spremljati glede prebijajočih glivnih okužb (glejte poglavje 4.2).
• patients who have a weak immune system due to having chemotherapy for “acute myelogenous leukemia” (AML) or “myelodysplastic syndromes” (MDS) 
• pri bolnikih z oslabljenim imunskim sistemom zaradi kemoterapije, potrebne za zdravljenje akutne mieloične levkemije (AML) ali mielodisplastičnih sindromov (MDS);
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively. 
Rifabutin (300 mg enkrat na dan) je zmanjšal Cmax (največjo plazemsko koncentracijo) posakonazola na 57 %, AUC posakonazola (površino pod krivuljo plazemske koncentracije v odvisnosti od časa) pa na 51 %.
Treatment of azole-susceptible Oropharyngeal Candidiasis (OPC) A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azolesusceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline). 
Zdravljenje orofaringealne kandidoze, občutljive na azole Randomizirana, s "slepim ocenjevalcem" kontrolirana študija je bila opravljena pri bolnikih, okuženih z virusom HIV, ki so imeli na azole občutljivo orofaringealno kandidozo (pri večini bolnikov v tej študiji so na začetku študije izolirali C. albicans).
Cav quartile analyses of pivotal patient studies with posaconazole tablet and oral suspension Posaconazole tablet 
Analiza kvartilov Cav ključnih študij pri bolnikih z uporabo tablet in peroralne suspenzije posakonazola
All drug interactions with posaconazole oral suspension, except for those that affect the absorption of posaconazole (via gastric pH and motility) are considered relevant to posaconazole concentrate for solution for infusion as well. 
Vsa medsebojna delovanja s posakonazolom v peroralni suspenziji razen tistih, ki vplivajo na absorpcijo posakonazola (zaradi pH v želodcu ali motilitete želodca), so pomembna tudi za posakonazol v koncentratu za raztopino za infundiranje.
An effect of renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended (see section 5.2). 
Vpliva okvare ledvic na farmakokinetiko posakonazola ni pričakovati, zato prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Noxafil should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm 
Pri bolnikih z akutno mieloično levkemijo ali mielodisplastičnimi sindromi je treba profilakso z zdravilom Noxafil začeti več dni pred pričakovanim pojavom nevtropenije in naj traja še 7 dni po zvečanju števila nevtrofilcev nad 500 celic/mm
The subject population for Cohorts 1 and 2 included subjects with AML or MDS who had recently received chemotherapy and had developed or were anticipated to develop significant neutropenia. 
Populacija preiskovancev za kohorti 1 in 2 je obsegala bolnike z AML ali MDS, ki so nedavno prejemali kemoterapijo in se jim je pojavila, ali je bilo pričakovano, da se jim bo pojavila pomembna nevtropenija.
Caution should be used when prescribing Noxafil to patients with hypersensitivity to other azoles. 
Pri predpisovanju zdravila Noxafil bolnikom, preobčutljivim na druge azole, je potrebna previdnost.
Noxafil can also be used to prevent fungal infections in adults who are at high risk of getting a fungal infection, such as: 
Zdravilo Noxafil se lahko uporabi tudi za preprečevanje glivnih okužb pri odraslih, ki imajo veliko tveganje za takšne okužbe, na primer:
Reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options (see section 4.5). 
Azolski antimikotiki, vključno s posakonazolom, naj bodo rezervirani za bolnike, ki prejemajo alkaloid vinke, vključno z vinkristinom, in ki nimajo alternativnih možnosti protiglivnega zdravljenja (glejte poglavje 4.5).
• some medicines used to treat or prevent fits including: phenytoin, carbamazepine, phenobarbital or primidone. 
• nekatera zdravila, ki se uporabljajo za zdravljenje ali preprečevanje epileptičnih napadov, med njimi fenitoin, karbamazepin, fenobarbital ali primidon.
Do not take Noxafil if you are taking any of the following: 
Ne jemljite zdravila Noxafil, če jemljete katero od naslednjih zdravil:
Accidental overdose was noted in one patient who took posaconazole oral suspension 1,200 mg twice a day for 3 days. 
Nenamerno preveliko odmerjanje je bilo zabeleženo pri enem bolniku, ki je 3 dni jemal peroralno suspenzijo posakonazola v odmerku 1.200 mg dvakrat na dan.
• pimozide (used to treat symptoms of Tourette's disorder) 
• pimozid (za zdravljenje simptomov Tourettovega sindroma)
Serial pharmacokinetic samples were collected on Day 1 and at steady-state on Day 14 for all Cohort 1 and 2 subjects and on Day 10 for a subset of Cohort 3 subjects. 
Zaporedne farmakokinetične vzorce so vzeli 1. dan in v stanju dinamičnega ravnovesja 14. dan vsem preiskovancem v kohorti 1 in 2 ter 10. dan podskupini preiskovancev v kohorti 3.
Excipient with known effect: Each vial contains 462 mg (20 mmol) sodium. 
Pomožna snov z znanim učinkom: Ena viala vsebuje 462 mg (20 mmol) natrija.
Alternatively, patients who can tolerate food or a nutritional supplement may take 400 mg (10 mL) twice a day during or immediately following a meal or nutritional supplement. 
200 mg (5 ml) štirikrat na dan. Bolniki, ki prenašajo hrano ali prehranske dodatke, lahko vzamejo 400 mg (10 ml) dvakrat na dan med ali takoj po jedi ali prehranskem dodatku.
• heart rhythm problems 
• težave s srčnim ritmom
You should not take this medicine if you have a condition called glucose-galactose malabsorption and should take note of this amount of glucose if you need to watch your sugar intake for any reason. 
To količino glukoze upoštevajte, če morate iz kakršnega koli razloga paziti na vnos sladkorja.
A key secondary endpoint was the incidence of proven/probable IFIs at 100 days post-randomisation. 
Ključni sekundarni opazovani dogodek je bila pojavnost dokazanih oziroma verjetnih invazivnih glivnih okužb 100 dni po randomizaciji.
The following medicinal products can be infused at the same time through the same intravenous line (or cannula) as Noxafil concentrate for solution for infusion: 
Po isti intravenski liniji (ali kanili) kot zdravilo Noxafil koncentrat za raztopino za infundiranje je hkrati mogoče infundirati naslednja zdravila:
Common: the following may affect up to 1 in 10 people 
Pogosti: pojavijo se lahko pri največ 1 od 10 oseb
• “pancytopenia” low level of all blood cells (red and white blood cells and platelets) shown in blood tests 
• pancitopenija - nizko število vseh krvnih celic (rdečih in belih krvnih celic ter trombocitov)
• Do not crush, chew, break or dissolve the tablet. 
• Tablete ne smete zdrobiti, žvečiti, prelomiti ali raztopiti.
Noxafil 40 mg/mL oral suspension posaconazole 
Noxafil 40 mg/ml peroralna suspenzija posakonazol
b: In 1899 this was the period from randomisation to last dose of study medicinal product plus 7 days; in 316 it was the period from first dose to last dose of study medicinal product plus 7 days. 
V študiji 1899 je bilo to obdobje od randomizacije do zadnjega odmerka preučevanega zdravila plus 7 dni, v študiji 316 pa je bilo to obdobje od prvega odmerka do zadnjega odmerka preučevanega zdravila plus 7 dni.
• a “statin” such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol. 
• katerega od statinov, na primer simvastatina, atorvastatina ali lovastatina, ki se uporabljajo za zdravljenje visokega holesterola.
• high level of “eosinophils” a type of white blood cell (eosinophilia) - this can happen if you have inflammation 
• visoko število eozinofilcev - vrste belih krvnih celic (eozinofilija) - pojavi se lahko, če imate kakšno vnetje
Noxafil is also available as 40 mg/mL oral suspension and 300 mg concentrate for solution for infusion. 
Zdravilo Noxafil je na voljo tudi kot peroralna suspenzija 40 mg/ml in 300 mg koncentrat za raztopino za infundiranje.
An increase in Cmax (26 %) and AUC (29 %) was observed in elderly subjects (24 subjects  65 years of age) relative to younger subjects (24 subjects 18 - 45 years of age). 
Pri starostnikih (24 preiskovancev, starih  65 let) so opažali povečanje Cmax (26 %) in vrednosti AUC (29 %) v primerjavi z mlajšimi preiskovanci (24 preiskovancev, starih od 18 do 45 let).
Administration instructions for Noxafil concentrate for solution for infusion 
Navodila za dajanje zdravila Noxafil koncentrat za raztopino za infundiranje
The pharmacokinetics of posaconazole are linear following single and multiple dose administration of up to 800 mg when taken with a high fat meal. 
Farmakokinetika posakonazola je linearna po enkratnem in večkratnem dajanju odmerkov do 800 mg, zaužitih z zelo mastno hrano.
The safety profile in these patients < 18 years of age appears similar to the safety profile observed in adults. 
Varnostni profil zdravila je pri teh bolnikih, mlajših od 18 let, videti podoben kot pri odraslih.
The excreted metabolites in urine and faeces account for approximately 17 % of the administered radiolabelled dose of posaconazole oral suspension. 
V urinu in blatu izločeni presnovki zajemajo približno 17 % uporabljenega radioaktivno označenega odmerka posakonazola v peroralni suspenziji.
Stevens Johnson syndrome, vesicular rash 
Stevens-Johnsonov sindrom, vezikularen izpuščaj
• midazolam, triazolam, alprazolam or other “benzodiazepines” (used as sedatives or muscle relaxants) 
• midazolam, triazolam, alprazolam in drugi benzodiazepini (uporabljajo se kot pomirjevala ali zdravila za sprostitev mišic),
The length of treatment may depend on the type of infection that you have or the length of time your immune system is not working properly and may be individually adapted for you by your doctor. 
Trajanje zdravljenja je lahko odvisno od vrste okužbe, ki jo imate, ali od tega, koliko časa vaš imunski sistem ne deluje pravilno.
If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. 
Če je potrebna sočasna uporaba, je bolnike priporočljivo skrbno spremljati glede prebijajočih glivnih okužb.
Noxafil 100 mg gastro-resistant tablets 
Noxafil 100 mg gastrorezistentne tablete